Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OraCAb
- Development stage
- Unknown
- Lead developer
- MicroPharm
- Modality
- Antibody-Based Therapeutics
- Administration
- Oral
01
Overview
OraCAb is an orally administered polyclonal antibody therapeutic developed by MicroPharm Limited in collaboration with the United Kingdom Health Security Agency (UKHSA) for the treatment of *Clostridioides difficile* infection (CDI). The drug consists of ovine-derived (sheep) polyclonal antibodies that specifically target and neutralize *C. difficile* Toxin A (TcdA) and Toxin B (TcdB) within the gastrointestinal tract. It features a specialized formulation designed to protect the antibodies from gastric and intestinal degradation, ensuring they remain active at the site of toxin production. Unlike traditional antibiotics, OraCAb treats mild to moderate CDI by neutralizing the pathogenic toxins directly without disrupting the commensal gut microbiota, which may help prevent infection recurrence and preserve colonic health.
- Brand names
- OraCAb
- Other names
- MicroPharm Clostridioides difficile antibodyovine polyclonal antibody (TcdA/TcdB)
02
Targets
TcdB (Clostridioides difficile large clostridial toxin family)TcdA (Clostridioides difficile toxin A)
Beyond the preview
Go deeper on OraCAb.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OraCAb.